Literature DB >> 15142364

Prognostic value of thyroglobulin serum levels and 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer.

Edelmiro Menéndez Torre1, María Teresa López Carballo, Rosa María Rodríguez Erdozáin, Lluís Forga Llenas, María José Goñi Iriarte, Juan José Barbería Layana.   

Abstract

Diagnostic iodine-131 whole-body scan ((131)I-WBS) and serum thyroglobulin values (Tg) performed 6 to 12 months after thyroid ablation for differentiated thyroid carcinoma were evaluated in 194 consecutive patients at the Hospital de Navarra, (Pamplona, Spain). All patients underwent near-total thyroidectomy and (131)I ablation with 3.7 GBq. Patients with positive anti-Tg antibodies or with (131)I uptake outside the neck were previously excluded. Uptake of (131)I in the thyroid bed was detected in 27 patients (13.9%). Serum Tg levels were below 0.5 ng/mL in 133 patients, ranged from 0.5-10 ng/mL in 39 patients, and was above 10 ng/mL in 22 patients. After a follow-up of 7.7 +/- 3.3 years, persistence of the illness has been observed in 2 patients with undetectable Tg (1.5%), but metastases were not detected in any case. In those with Tg higher than 0.5 ng/mL, 29 of 61 patients had persistence of the disease (47.5%) with evidence of metastases in 15 (24.5%), irrespective of the initial total body scan (131)I uptake. In conclusion, serum Tg levels obtained after thyroid ablation has a good prognostic value and permits the selection of patients for further diagnostic studies, while diagnostic (131)I-WBS performed at that time did not correlate with results of Tg and scarcely provides additional information.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142364     DOI: 10.1089/105072504323030960

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT.

Authors:  Parveen Kundu; Sneh Lata; Punit Sharma; Harmandeep Singh; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

2.  Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.

Authors:  Marie-Odile Bernier; Olivier Morel; Patrice Rodien; Jean-Pierre Muratet; Philippe Giraud; Vincent Rohmer; Christian Jeanguillaume; Jean-Claude Bigorgne; Pierre Jallet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

3.  Clinical implication of cancer adhesion in papillary thyroid carcinoma: clinicopathologic characteristics and prognosis analyzed with degree of extrathyroidal extension.

Authors:  Seung Pil Jung; Minkuk Kim; Jun-Ho Choe; Jee Soo Kim; Seok Jin Nam; Jung-Han Kim
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

4.  Clinical use of PET/CT in thyroid cancer diagnosis and management.

Authors:  Fx Sundram
Journal:  Biomed Imaging Interv J       Date:  2006-10-01

5.  Differentiated thyroid cancer in navarra (Spain): historic cohort results (1987-2003).

Authors:  María Pilar Salvador Egea; Ana Aranzazu Echegoyen Silanes; Eduardo Layana Echezuri; Emma Anda Apiñariz; Ana Puras Gil; Edelmiro Menéndez Torre; Lluis Forga Llenas; Amaya Sainz de Los Terreros
Journal:  ISRN Oncol       Date:  2011-07-31

6.  Diffuse skeletal metastasis and low thyroglobulin level in a pediatric patient with papillary thyroid carcinoma.

Authors:  Seyed Rasoul Zakavi; Narjess Ayati; Jamshid Farahati; Behrooz Davachi
Journal:  Indian J Nucl Med       Date:  2015 Jul-Sep

7.  Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma?

Authors:  Se Jun Choi; Tae Yong Kim; Jong Cheol Lee; Young Kee Shong; Kyoung-Ja Cho; Jin Sook Ryu; Jeong Hyun Lee; Jong-Lyel Roh; Sang Yoon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-03-20       Impact factor: 3.372

8.  The diagnostic value of 124I-PET in patients with differentiated thyroid cancer.

Authors:  Ha T T Phan; Pieter L Jager; Anne M J Paans; John T M Plukker; M G G Sturkenboom; W J Sluiter; Bruce H R Wolffenbuttel; Rudi A J O Dierckx; Thera P Links
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.